Medical News Today: What can cause anal swelling?
Many factors can cause anal swelling, or a swollen anus, which can be itchy or painful. Home remedies and treatments can help. Learn more here.
In this study, we examined the anti-inflammatory property of an ethanol fraction (EEF6) fromR. minima root on lipopolysaccharide (LPS)-induced RAW 264.7 cells, as well as its underlying mechanism. The compound composition of EEF6 was determined by high-performance liquid chromatography-mass spectrometry. The result showed that five flavonoids compounds, 2 ′,4′,5,7-tetrahydroxyisoflavone, genistein-8-C-glucopyranoside, tricin, genistein, and daidzein, were identified in EEF6. In addition, EEF6 exhibited potent anti-inflammatory ability against LPS-stimulated RAW 264.7 cells via MAPK/NF- κB signaling pathwa...
HER3/ErbB3 receptor deletion or blockade leads to tumor cell apoptosis, whereas its overexpression confers anti-cancer drug resistance through upregulation of protective mechanisms against apoptosis. We produc...
ECZEMA is a common condition that results in red, dry and itchy patches of skin. What are four ways to help alleviate the skin condition?
A 39-year-old male, live-related renal transplant recipient with stable graft function presented with multiple painless, non-itchy, papular lesions over the midback region. Three months later, these lesions became multiple abscesses with pus exudation (Figure 1). The patient had a history of injury to his midback from the sharp edge of cement stairs, which caused an abrasion. He had received a thymoglobulin induction and was on prednisolone, tacrolimus, and azathioprine. The microscopic examination of KOH mount of pus revealed multiple, septate, branch ing, brown-pigmented hyphae with thick-walled vesicular swellings...
ECZEMA is a condition where patches of skin become inflamed, itchy, red, cracked, and rough. The condition is sometimes called “the itch that rashes.” What is the best treatment to help ease symptoms of eczema?
Atopic dermatitis (AD) is characterized by skin lesions and pruritus not relieved by scratching. The challenge for current therapies is to treat both of these characteristic disease symptoms. Many of the currently available therapies improve AD through clearing of the skin by targeting improvement in lesion severity. Targeting AD improvement through reduction in pruritus remains a significant unmet medical need. Tradipitant, a novel neurokinin-1 receptor antagonist, is a possible therapy that could improve AD through reduction in pruritus.
Healthy skin is colonized with a diverse population of microorganisms and typically harbors higher microbial diversity than atopic skin. Despite this understanding, there is little known about the microbiome of dry skin as compared with normal skin and how microbial populations are affected by use of topical products. A single-center, evaluator-blinded, randomized, split-leg clinical trial was conducted to evaluate the efficacy of two treatment regimens on the lower legs of 76 female subjects, ages 18-55, with clinically graded dry or dry/itchy skin.
Multiple innate immune signaling pathways become activated upon skin injury in order to reestablish the antimicrobial barrier and prevent infection. Damage to the skin barrier often elicits pain and/or itch, and leads to activation of the nervous system which communicates intimately with the immune system in a variety of skin inflammatory conditions (Kashem&Kaplan, 2016; Riol-Blanco et al. 2014, Chiu et al. 2013, Ding et al. 2016). Given that sensory dorsal root ganglion neurons express toll-like receptors that sense viral nucleic acids (Chiu et al.
Background: Chronic pruritus is a distressing medical condition that is associated with significantly decreased quality of life and multiple comorbidities. There are currently no FDA approved therapies specifically for the treatment of chronic itch, and off-label treatment is often times used for patients with severe itch. Recent literature suggests that the antiinflammatory and analgesic properties of cannabis make cannabinoid therapy an option for dermatologic conditions, especially in the treatment of chronic pruritus.
Background: This analysis reports baseline characteristics of patients with prurigo nodularis (PN) enrolled in a study of serlopitant (NCT02196324), one of the largest randomized controlled trials conducted to date in this patient population, and assesses the impact of treatment on sensory qualities of PN.